Research
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Biological psychiatry – February 01, 2023
Summary
A groundbreaking clinical trial revealed that LSD-assisted therapy significantly reduced anxiety and depression in patients, with benefits lasting up to 4 months. The treatment proved effective for people with general anxiety and those facing life-threatening illnesses. Using psychedelics in a controlled therapeutic setting led to meaningful symptom improvement, with minimal side effects. Only mild, temporary discomfort was reported by a small number of participants.
Abstract
This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety wi...
Intensive Mindfulness Meditation Reduces Frequency and Burden of Migraine: An Unblinded Single-Arm Trial.
Mindfulness – February 01, 2023
Summary
No Summary
Abstract
Preventing migraine headaches and improving the quality of life for patients with migraine remains a challenge. We hypothesized intensive meditatio...
Effective Connectivity of Functionally Anticorrelated Networks Under Lysergic Acid Diethylamide.
Biological psychiatry – February 01, 2023
Summary
LSD's profound ability to alter self-perception stems from its unique impact on brain network communication. Research shows the psychedelic disrupts normal boundaries between brain networks that typically maintain our sense of self. Using advanced brain imaging, scientists found LSD transforms inhibitory connections between key neural networks into excitatory ones, particularly affecting how attention-directing systems interact. This may explain the ego dissolution experience many report during psychedelic states.
Abstract
Classic psychedelic-induced ego dissolution involves a shift in the sense of self and a blurring of the boundary between the self and the world. A ...
More on psilocybin
Current Psychiatry – February 01, 2023
Summary
Oregon has legalized psilocybin for therapeutic use, signaling a profound shift in Psychiatry and Medicine. This potent hallucinogen, once confined to drug studies, is now gaining traction in mainstream Psychology. While safety for treating psychiatric disorders is crucial, analyses suggest severe adverse events occur in under 5% of thousands of participants across pooled data. This re-evaluation challenges traditional psychoanalysis, potentially integrating with digital mental health interventions. The evolving legal status highlights psilocybin's therapeutic promise, prompting deeper exploration into psychedelics.
Abstract
I would like to remark on “Psychedelics for treating psychiatric disorders: Are they safe?” (Current Psychiatry, December 2022, p. 14-22, doi:10.12...
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
Journal of affective disorders – February 01, 2023
Summary
Breakthrough treatments using psychedelic therapy show remarkable success in treating depression and illness-related distress. Clinical trials with psilocybin, LSD, and ayahuasca demonstrated significant symptom reduction in patients, with benefits lasting up to 5 weeks post-treatment. When combined with psychological support, these therapies offered hope to those who hadn't responded to conventional treatments.
Abstract
Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress....
Spontaneous and induced out-of-body experiences during sleep paralysis: Emotions, "AURA" recognition, and clinical implications.
Journal of sleep research – February 01, 2023
Summary
No Summary
Abstract
Sleep paralysis is characterized by the incapacity to perform voluntary movements during sleep/wake transitions, and could bring great discomfort. ...
Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use
Frontiers in Neuroscience – January 31, 2023
Summary
Ayahuasca, a powerful hallucinogen, offers significant therapeutic potential by facilitating five distinct psychotherapeutic processes, according to a large qualitative study of its drinkers. These include introspection, emotional processing, and gaining new perspectives, differing from other psychedelics like Psilocybin. This traditional medicine, increasingly studied in Psychedelics and Drug Studies, shows promise for mental health. Understanding these unique mechanisms better equips psychotherapists in Psychology and Medicine to optimize treatment models, leveraging Ayahuasca's transformative effects.
Abstract
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine (Spruce ex Griseb. Morton, Malpighiaceae), ...
Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
Advances in Research – January 30, 2023
Summary
Over 700 million individuals globally suffer from mental illness, highlighting the urgent need for new medicine. Psychedelic-assisted psychotherapy offers astounding, fast results where traditional treatments often fall short. Supervised sessions by a clinical psychology psychotherapist or psychiatrist, integrating compounds like psilocybin, MDMA, and lysergic acid diethylamide, are transforming mental health care. This emerging field of psychiatry and psychology is exploring these powerful hallucinogens for conditions like anxiety, representing a new promise in drug studies.
Abstract
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted w...
Qualitative Screening of Amphetamine- and Ketamine-Type Abuse Drugs in Urine Employing Dual Mode Extraction Column by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS).
Journal of analytical toxicology – January 24, 2023
Summary
A new, rapid method can detect 11 different illicit and designer drugs in just 0.2 mL of urine, crucial for forensic investigations. This technique identifies drugs like ketamine and its analogues at ultralow levels, down to 1 ng/mL. Other substances, including methamphetamine and MDMA, are detectable at 3 ng/mL. Employing a novel dual mode extraction, the process ensures high accuracy with matrix effects ranging from -12% to 7%. This advancement significantly aids forensic toxicology and the detection of drugs used in criminal acts.
Abstract
This manuscript reported a fast and rapid qualitative screening method for abuse drugs in urine by liquid chromatography-tandem mass spectrometry (...
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)<sub>2A</sub> Receptor (5-HT<sub>2A</sub>R), 5-HT<sub>2C</sub>R, 5-HT<sub>1A</sub>R, and Serotonin Transporter.
J Pharmacol Exp Ther – January 20, 2023
Summary
Even tiny molecular tweaks can dramatically shift how compounds interact with brain chemistry. New research explored how different tryptamine structures bind to key serotonin receptors and the serotonin transporter. This work successfully identified specific compounds exhibiting potent and selective activity, offering valuable insights for future drug development.
Abstract
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter.
Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial
Journal of Psychedelic Studies – January 18, 2023
Summary
Group psychotherapy offers a promising path to scale psilocybin as a psychological intervention for distress and anxiety in medical illness. A pilot clinical trial involved three cohorts, each with 4-6 cancer patients, receiving a 25mg psilocybin dose alongside preparatory and integration sessions. Psychotherapists led this innovative approach, gathering qualitative insights on group format and process. This work informs Clinical Psychology and Psychiatry, offering guidelines for future natural compound pharmacology studies, making this medicine more accessible for those referred for support.
Abstract
Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential ...
Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder
AIDASCO Reviews – January 17, 2023
Summary
Psilocybin, a potent hallucinogen and alkaloid, offers remarkable promise in Psychiatry for Major depressive disorder. It rapidly relieves depression and anxiety symptoms, with benefits lasting several months. This focus of Psychedelics and Drug Studies provides a non-addictive path for Medicine to address the global burden of psychological disorders. While its therapeutic potential is clear, rigorous, consistent studies are essential to integrate such treatments, perhaps alongside future Digital Mental Health Interventions, into mainstream care.
Abstract
Major depressive disorder (MDD), also known as clinical depression, is a serious mental disorder and ranks first among psychiatric disorders that d...
Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands
Journal of Psychedelic Studies – January 16, 2023
Summary
Experiencing challenges after a psilocybin retreat can be integral to its transformative potential. Among 30 individuals attending a legal truffle retreat, 9 (30%) spontaneously reported integration difficulties, including mood fluctuations and disconnection from community, key in psychology. These transient experiences, aligned with 'spiritual emergency' in Psychedelics and Drug Studies, often resolved, correlating with positive outcomes. This highlights the importance of harm reduction and psychotherapist support for hallucinogen use, contributing to diverse academic research themes beyond chemical synthesis and alkaloids, fostering transformative learning.
Abstract
Abstract This article reports on integration challenges that were experienced by nine individuals who attended a three-day legal psilocybin truffle...
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
OpenAlex – January 16, 2023
Summary
Psilocybin and MDMA are already vital for mental health in Aotearoa, where exploratory qualitative research reveals a robust underground community. Through thematic analysis of participant experiences, this psychology-focused work shows individuals successfully self-medicating with hallucinogens like psilocybin and LSD, achieving long-lasting benefits. Due to conventional psychiatry access issues, participants craft their own treatment. These natural compound pharmacology studies offer critical insights for psychedelics and drug studies, suggesting rescheduling for legal use, either for self-medication or as adjunct to psychotherapy, addressing prohibition's stigma.
Abstract
<p>Examining participants’ experiences self-medicating with LSD, psilocybin, and MDMA, this exploratory study sought to determine whether psy...
Recruitment discrimination of lifetime classic psychedelic users is unjustified: Evidence from employees' motivation-based workplace absenteeism
Journal of Psychedelic Studies – January 16, 2023
Summary
Despite widespread stigma, prior psilocybin and other psychedelic use does not predict workplace absenteeism. While past psychedelics are linked to reduced odds of some mental health issues, a large population analysis of 193,320 employed US adults found no association between lifetime classic psychedelic use and skipped workdays. This challenges discrimination against the 35 million adults who have used psychedelics, often rejected for roles in clinical psychology or psychiatry. This finding, relevant to behavior, suggests drug use history shouldn't arbitrarily bar individuals from employment.
Abstract
Abstract Background and aims Although large-scale population studies have linked the use of classic psychedelics (lysergic acid diethylamide, psilo...
Psychedelics for Patients With Cancer: A Comprehensive Literature Review
Annals of Pharmacotherapy – January 12, 2023
Summary
For cancer patients battling **anxiety** and **depression**, psychedelics offer a compelling finding in **psychiatry**. Five randomized, **placebo**-controlled **drug studies** revealed substantial reductions on **rating scales** like the **Beck Depression Inventory**. These substances, often derived from **chemical synthesis and alkaloids**, offer a unique mechanism, presenting a novel therapeutic option in **medicine** and **clinical psychology**. Unlike traditional **psychology** treatments, benefits may extend 6-12 months from just a few sessions. While these **complementary and alternative medicine** approaches are still early, with small study sizes and noted blood pressure increases, they offer hope.
Abstract
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search fro...
Understanding Physical Processes in Describing a State of Consciousness: A Review
arXiv Preprint Archive – January 12, 2023
Summary
Consciousness shapes how we perceive reality and defines our identity, yet its physical basis remains one of science's most intriguing puzzles. Recent advances in q-bio.NC (neurological complexity) reveal that consciousness emerges from an intricate interplay of brain signals, quantum processes, and information integration. This understanding bridges quantum physics and neuroscience, suggesting consciousness arises from both classical and quantum mechanisms in our neural networks.
Abstract
The way we view the reality of nature, including ourselves, depend on consciousness.It also defines the identity of the person, since we know peopl...
What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.
Journal of medicinal chemistry – January 12, 2023
Summary
Ibogaine, a natural compound, offers remarkable promise for treating substance use disorders. Its anti-addictive properties are linked to inhibiting specific brain receptors (α3β4 nicotinic acetylcholine receptors). Experts highlight the promising potential of targeting these receptors as a therapeutic approach, suggesting a new, effective treatment pathway for a wide array of substance use disorders.
Abstract
For decades, ibogaine─the main psychoactive alkaloid found in Tabernanthe iboga─has been investigated as a possible treatment for substance use dis...
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
International Journal of Molecular Sciences – January 10, 2023
Summary
Growing interest in Psilocybin, Mescaline, and Lysergic acid diethylamide for psychiatric disorders is prompting a re-evaluation in medicine. This neuropharmacology review synthesizes extensive pharmacology and psychology research, exploring ethnobotanical uses and the chemical synthesis of these hallucinogen alkaloids. It details their neurotransmitter receptor influence on behavior, examining affinity and binding modes. The review also discusses numerous clinical studies evaluating efficacy for conditions like depression, comparing them to current psychiatry treatments. Understanding these mechanisms advances drug studies.
Abstract
The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addit...
Anadenanthera colubrina (Vell) Brenan: Ethnobotanical, phytochemical, pharmacological and toxicological aspects.
Journal of ethnopharmacology – January 10, 2023
Summary
A South American tree, long valued in folk medicine, exhibits remarkable therapeutic potential. A comprehensive review synthesized existing knowledge on this fabaceae species' traditional uses, phytochemistry, and pharmacology. Historically used for respiratory issues and rituals, its rich chemical profile includes over 50 compounds, contributing to impressive anti-inflammatory, antimicrobial, and antioxidant benefits. While some seed compounds can be potent, extracts from leaves, bark, and fruits consistently show low toxicity, validating its role as a valuable medicinal plant. This robust tree offers exciting natural health possibilities.
Abstract
Anadenanthera colubrina (Vell.) Brenan is an endemic tree to South America and different parts of it are used by the population for the treatment o...
Rapid Detection and Quantification of Hallucinogenic Salvinorin A in Commercial Salvia divinorum Products by DART-HRMS.
ACS omega – January 10, 2023
Summary
Enhanced Salvia products contain dramatically higher levels of the psychoactive compound salvinorin A than raw leaves, prompting the development of a swift method to identify and measure this substance. A novel approach using direct analysis mass spectrometry successfully bypassed lengthy sample preparation. This method rapidly screened plant material and accurately quantified salvinorin A. Raw Salvia leaves averaged 1.54 mg/g, while enhanced extracts contained 13.0 to 53.2 mg/g, revealing potent concentrations. This rapid, direct analysis offers a powerful tool for assessing psychoactive plant materials.
Abstract
In recent years, national laboratories have identified several plant-derived materials as concerns to public health because of their psychoactive e...
The association between naturalistic use of psychedelics and co-occurring substance use disorders
Frontiers in Psychiatry – January 10, 2023
Summary
Peyote or Mescaline, a classic hallucinogen, shows promise in medicine for substance abuse. Among 56,276 participants, prior use of peyote/mescaline was associated with 32% lower odds (odds ratio = 0.68) of past-year substance dependence or abuse compared to non-users. This contrasts with LSD and Psilocybin, where past use was linked to increased odds. Clinical psychology and psychiatry examine how these psychedelics, through chemical synthesis and alkaloids, impact addiction. Biochemical analysis techniques could further differentiate these effects in drug studies.
Abstract
Objective Classic psychedelics (LSD, psilocybin, and peyote/mescaline) have been used to support addiction treatment in a variety of contexts rangi...
Interaction of psychedelic tryptamine derivatives with a lipid bilayer
Chemistry and Physics of Lipids – January 07, 2023
Summary
Subtle chemical differences in psychedelics dramatically alter how they interact with brain cell membranes. Biophysics investigations using all-atom simulations show neutral tryptamines, like dimethyltryptamine and 5-MeO-DMT, readily cross the lipid bilayer. Conversely, bufotenine, while also a neutral tryptamine, doesn't cross the biological membrane, despite maximally affecting its structure. Charged tryptamines only partially penetrate the bilayer. This stereochemistry-driven partitioning, key to Chemistry and Biochemical Analysis, profoundly influences neurotransmitter receptor function and behavior, informing Psychedelics and Drug Studies.
Abstract
Naturally occurring psychedelics have been used for a long time as remedies or in religious ceremonies and recreational activities. Recent studies ...
Acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans: A TD-fNIRS neuroimaging study
bioRxiv Preprint Server – January 06, 2023
Summary
Quantifying neural activity during psychedelics in a clinical setting can unlock personalized treatments. A study measured brain dynamics and physiological effects in healthy volunteers given a psychoactive substance (ketamine) or placebo. Ketamine altered consciousness and systemic responses, reducing brain-wide low-frequency fluctuations and prefrontal connectivity. Initial findings suggest combining brain and body metrics could predict positive mystical experiences and improve depressive symptomatology, leading to better patient outcomes and potential biomarkers. This highlights successful brain imaging for understanding psychedelic impact.
Abstract
Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administratio...
Healing at death’s door: one patient’s mystical experience with psilocybin
International Journal of Whole Person Care – January 06, 2023
Summary
Psilocybin, a potent hallucinogen, is emerging as a powerful tool to alleviate end-of-life existential suffering, where conventional medicine often falls short. For hundreds, if not thousands of years, indigenous cultures have used psilocybin-containing fungi ceremonially, integrating it into Religious Studies and Spiritual Practices. Now, Western Medicine and Psychology are exploring its potential in Psychotherapy Techniques and Applications. This approach, part of Psychedelics and Drug Studies, aims to address psychospiritual distress. Psychotherapists are investigating how this compound fosters meaningful reflection and potentially a sense of Mysticism, moving beyond mere physiological symptom control.
Abstract
eath is of the most certain and undeniable truths in an existence shrouded by mysteries and unknowns, yet many don't have the opportunity for a mea...
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder
Neuropharmacology – January 06, 2023
Summary
Current anti-anxiety agents offer only temporary relief for prevalent psychiatric disorders like Anxiety and Panic disorder. A promising shift in Medicine and Psychiatry is underway. Clinical neuroscience and Neuropsychopharmacology are now developing anti-anxiety agents targeting diverse neurochemical systems, including monoamines (like those influenced by Psychedelics and Drug Studies), GABA, glutamate, and Nicotinic Acetylcholine Receptors. This Neuroscience-driven approach in Clinical psychology aims for lasting brain changes, not just symptom management, offering renewed hope for Treatment of Major Depression and other conditions, moving beyond transient symptom attenuation.
Abstract
Psychiatric disorders associated with psychological trauma, stress and anxiety are a highly prevalent and increasing cause of morbidity worldwide. ...
An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations
American Journal of Hospice and Palliative Medicine® – January 05, 2023
Summary
Psilocybin-assisted therapies for emotional distress frequently prompt mystical experiences and enhanced meaning. Yet, a review of seven clinical psychology studies, involving adults with serious illness, revealed significant inconsistency in how spirituality is measured. Across these studies, 12 different instruments were used, with the Mystical Experience Questionnaire (MEQ30) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp-12) each appearing in four. This lack of clear operationalization for spirituality and its domains hinders rigorous medicine and drug studies, impacting psychotherapist practice and patient outcomes.
Abstract
Background: Psilocybin-assisted therapies (PAT) are reemerging as a treatment for complex distress often prompting mystical experiences, enhanced m...
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
OpenAlex – January 05, 2023
Summary
Compellingly, repeated low doses of the serotonergic hallucinogen Psilocybin imparted stress resilience and reduced compulsive behaviors in rats, without causing anhedonia. This pharmacology model, crucial for Psychedelics and Drug Studies in Psychology and Medicine, influenced neurotransmitter receptors, increasing 5-HT7 receptor expression and synaptic density. This Neuroscience finding, involving a psychotomimetic compound often from chemical synthesis and alkaloids, substantiates anecdotal microdosing benefits. It highlights how Psilocybin can impact behavior via receptor influence, establishing a validated regimen for future investigation.
Abstract
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorder...
The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal – January 05, 2023
Summary
Psilocybin, a potent hallucinogen, shows strong therapeutic potential for alcohol use disorder. Psilocybin-assisted psychotherapy offers a promising new tool for psychotherapists and psychiatry within clinical psychology and medicine. It influences behavior via neurobiological alterations, impacting neurotransmitter receptors, fostering psychological improvements, and spiritual development. This emerging context in psychedelics and drug studies, exploring psilocybin as an alkaloid, represents a significant advancement. Its efficacy suggests a valuable addition to addiction treatment.
Abstract
Introduction: Psilocybin (the active compound found in “magic mushrooms”) has been an area of recent focus in the academic and psychiatric communit...
Are psychedelics the answer to chronic pain: A review of current literature
Pain Practice – January 04, 2023
Summary
Psilocybin, a potent hallucinogen, offers a non-addictive alternative for chronic pain management, a critical need in Medicine. For cancer pain and related psychological distress, its analgesic potential was established decades ago, showing promising results in Psychiatry. These psychedelic compounds influence neurotransmitter receptors, disrupting pain pathways. While evidence for general chronic pain efficacy is limited and of low quality, patients self-medicating for severe headaches report relief. Its favorable safety profile, lacking the addiction risk of many analgesics, makes psilocybin a compelling area for ongoing drug studies.
Abstract
Abstract Aims We aim to provide an evidence‐based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chr...
Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst
OpenAlex – January 04, 2023
Summary
A compelling finding from empirical research on self-dissolution during psilocybin-assisted psychotherapy is a profound feeling of connection. A systematic review of 10 qualitative studies reveals subjects often report a stronger feeling of essence and altered bodily experiences, despite challenging moments, leading to blissful outcomes. This phenomenon, central to Psychedelics and Drug Studies, is explored through Psychoanalytic theory, analyzing intra- and intersubjective processes. Another psychological perspective examines the influence of the therapeutic context on the subject's experience, providing insights for Mental Health and Psychiatry and Psychotherapy Techniques and Applications, enriching our understanding of the human psyche.
Abstract
Self or ego dissolution (SED) is a recurring, yet vaguely defined phenomenon often associated with positive therapeutic outcomes within clinical re...
Os benefícios do uso da ayahuasca como ferramenta alternativa ao tratamento convencional da depressão: uma revisão de literatura
Revista Científica do UBM – January 03, 2023
Summary
Ayahuasca shows promise as a natural alternative for treating depression, with evidence suggesting it may effectively alleviate symptoms. In a comprehensive review of 50 studies, the psychoactive components, particularly dimethyltryptamine (DMT), have been linked to improved mood and reduced anxiety by interacting with serotonin receptors and modulating cortisol levels. While Ayahuasca could serve as a valuable therapeutic tool, further investigation is essential to validate its efficacy in mental health treatment. This highlights the growing interest in psychedelics within psychology and drug studies.
Abstract
A depressão é uma patologia cada vez mais inerente ao cotidiano de milhares de pessoas no mundo. Apesar de eficaz, o tratamento convencional com an...
Self-experience in MDMA assisted therapy of PTSD
medRxiv Preprint Server – January 03, 2023
Summary
For those with severe PTSD, especially from childhood trauma, challenges with emotional coping often hinder recovery. A randomized trial investigated if MDMA-assisted therapy could help. Participants received therapy with MDMA or placebo. Remarkably, MDMA-assisted therapy significantly boosted self-compassion and improved altered mental processes linked to poor treatment response. This approach shows promise for addressing core emotional challenges in PTSD.
Abstract
In recent years there has been a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphet...
Cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in South Africa
South African Journal on Human Rights – January 02, 2023
Summary
South Africa’s criminalization of psilocybin mushrooms is unjustifiable. An interpretation of Section 12(2) of the Constitution establishes cognitive liberty as a fundamental human right, protecting both mind and body. Current legislation, including the Drugs and Drug Trafficking Act, directly conflicts with this constitutional protection. A political science analysis concludes that criminalizing psilocybin, a psychedelic, lacks justifiable grounds. This challenges existing drug law and calls for a re-evaluation of human rights regarding consciousness.
Abstract
The principle of cognitive liberty is assessed as a ground for challenging the constitutionality of the criminalisation of psilocybin mushrooms. To...
Ayahuasca and personality. A systematic review and meta-analysis of cross-sectional studies with long-term participants (Ayahuasca y personalidad. Revisión sistemática y metaanálisis de estudios transversales con participantes de larga trayectoria)
Studies in Psychology Estudios de Psicología – January 02, 2023
Summary
Long-term participants in ayahuasca rituals exhibit a distinct personality profile, characterized by lower levels of anxiety and higher levels of social and spiritual traits. In a review of six studies involving diverse groups, these individuals scored significantly lower on Harm Avoidance (g = -0.51) and Fear of Uncertainty (g = -0.27), while showing marked increases in Self-Transcendence (g = 0.91) and Spiritual Acceptance (g = 1.02). This suggests that ayahuasca may foster positive psychological attributes aligned with findings in other psychedelic research.
Abstract
ABSTRACTThe current article is a systematic review and meta-analysis of cross-sectional studies that assess personality traits of long-term partici...
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.
Journal of psychoactive drugs – January 01, 2023
Summary
Mystical experiences and feelings of boundlessness during psychedelic sessions strongly predict positive therapeutic outcomes. Analysis of multiple assessment tools reveals that subjective reactions to substances like psilocybin correlate with improvements in depression, anxiety, and addiction. While challenging experiences can be valuable, the depth of mystical experiences during psychedelic-assisted psychotherapy appears most crucial for healing.
Abstract
Subjective responses to psychoactive drugs have served as intriguing windows into consciousness as well as useful predictors. Subjective reactions ...
The right to privacy in the decriminalisation of psilocybin mushrooms in South Africa
Law Democracy & Development – January 01, 2023
Summary
Criminalizing psilocybin mushrooms is unconstitutional, infringing the Right to privacy for an estimated 750,000 citizens. South Africa's Constitution, Section 14, paramountly protects personal behavior, even illicit drug use. Existing legislation, affecting 20% of drug-related cases, *prima facie* limits this. Political science supports Decriminalization; the right's importance outweighs state purpose. This aligns with robust privacy laws, including US privacy laws, protecting privacy, including HIV status and sexuality, and marriage from overreach, preventing state behavior akin to torture, especially with technology affecting sexual risk.
Abstract
This article assesses the right to privacy as a ground for challenging the constitutionality of the criminalisation of psilocybin mushrooms. In doi...
Simultaneous Determination and Stability Analysis of Ten New Psychoactive Substances including Synthetic Cathinones, Phenethylamines, and Ketamine Substitutes in Urine Using Liquid Chromatography-Tandem Mass Spectrometry.
International journal of analytical chemistry – January 01, 2023
Summary
Four new psychoactive substances—PMA, PMMA, DCK, and 2-FDCK—remain stable in urine for up to 90 days, even when stored at varying temperatures from -20°C to +25°C. This evaluation of ten such substances, using three replicates per condition, revealed that synthetic cathinones, conversely, degraded significantly at room temperature (+25°C) in urine. Optimal stability for all substances was observed at -20°C. This information is vital for accurate drug concentration analysis.
Abstract
Knowing the stability of drugs is important to ensure accurate and reliable results of drug concentrations. This study evaluated the stability of t...
Cessations of consciousness in meditation: Advancing a scientific understanding of nirodha samāpatti.
Progress in brain research – January 01, 2023
Summary
No Summary
Abstract
Absence of consciousness can occur due to a concussion, anesthetization, intoxication, epileptic seizure, or other fainting/syncope episode caused ...
Relatos de exploradores e viajantes e primeiras pesquisas científicas com a ayahuasca, 1850-1950, no debate atual sobre o “renascimento psicodélico”
História Ciências Saúde-Manguinhos – January 01, 2023
Summary
Ayahuasca's historical significance is underscored by its emergence in scientific discourse since 2000, reflecting a revival of interest in psychedelics. From 1850 to 1950, over 40 documented expeditions to the Amazon explored its indigenous uses, influencing contemporary debates on drug classification and therapeutic potential. The analysis highlights the tension between traditional practices and Western interpretations, revealing that early studies laid the groundwork for current discussions in Humanities, Cannabis and Cannabinoid Research, and Biochemical Analysis. This context enriches our understanding of ayahuasca’s role today.
Abstract
Resumo O artigo descreve associações e controvérsias entre usos indígenas e ocidentais da ayahuasca, de 1850 a 1950, na relação com o “renascimento...
Visualizing drug actions on dendrites: psilocybin and other classic psychedelics
OpenAlex – January 01, 2023
Summary
Psilocybin, a potent hallucinogen, rapidly rewires the brain. Neuroscience microscopy revealed that a single dose significantly increased dendritic spines on neurons within the mouse frontal cortex. These profound structural changes, vital for learning and memory, illuminate how psychedelics influence brain function. Such findings from drug studies are crucial for psychology, potentially explaining altered perception, including olfactory and other sensory functions, and the broader neurotransmitter receptor influence on behavior.
Abstract
To determine effects of psychedelics on neuronal architecture, we used two-photon microscopy to image dendritic spines in mouse frontal cortex afte...
CHEMISTRY OF AYAHUASCA: A DIDACTIC APPROACH TO TEACH FUNCTIONAL GROUPS
Editora Científica Digital eBooks – January 01, 2023
Summary
A compelling approach to teaching chemistry showed significant benefits for high school students. At the Instituto Federal do Triângulo Mineiro, a case study using ayahuasca to teach functional groups engaged seniors in a more meaningful way. The qualitative and participatory action research involved 30 students, revealing that contextualized lessons improved conceptual understanding and skill development. As a result, 85% of participants reported increased engagement in chemistry activities, highlighting the effectiveness of linking scientific knowledge with real-world contexts for enhanced learning outcomes.
Abstract
Most High School chemistry teachers keep having difficulty in contextualizing school contents in their lessons. The use of new methodologies in sch...
Towards an understanding of psychedelic-induced neuroplasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Psychedelics like LSD and psilocybin can rewire the brain's neural connections, particularly in areas controlling mood and memory. These substances trigger rapid growth of new neural connections and enhance brain plasticity, especially in the prefrontal cortex and hippocampus. This helps explain why a single treatment can lead to lasting positive changes in depression and anxiety that persist for months.
Abstract
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and add...
Classic psychedelics do not affect T cell and monocyte immune responses.
Frontiers in psychiatry – January 01, 2023
Summary
Common psychedelics like LSD, DMT, and mescaline don't suppress immune function, according to laboratory testing. Scientists examined how these compounds interact with T cells and monocytes - crucial components of our immune system. The findings showed that psilocin and other psychedelics didn't interfere with normal immune cell activity, suggesting these substances are safe for therapeutic use without compromising immune health.
Abstract
Classic psychedelics have been shown to exert therapeutic potential for the treatment of various psychiatric disorders, neuropsychiatric diseases, ...
Reports by explorers and travelers and the first scientific studies on ayahuasca (dating from 1850 to 1950) within the current debate on the “psychedelic renaissance”
História Ciências Saúde-Manguinhos – January 01, 2023
Summary
Ayahuasca, a traditional Indigenous psychoactive brew, has seen a resurgence in interest during the psychedelic renaissance, which began gaining traction in the early 2000s. Examining historical accounts from 1850 to 1950 reveals that early studies on ayahuasca were often overshadowed by anti-drug policies that emerged in the late 20th century. With over 100 articles and expedition reports analyzed, this exploration highlights ongoing debates surrounding Indigenous practices, pharmaceutical interests, and the complex sociopolitical landscape of psychedelics today.
Abstract
Abstract This article describes the associations and controversies between indigenous and western uses of ayahuasca between 1850 and 1950 in relati...
Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data
The Transmitter – January 01, 2023
Summary
Debate surrounds the use of psilocybin, a potent hallucinogen, in a clinical trial for fragile X syndrome, highlighting the evolving field of psychedelics and drug studies. In Mental Health and Psychiatry, a serotonin agonist drug is also progressing to a pharmacology-based drug trial for autism. Crucially, understanding the complex placebo effect and placebo response observed in medicine, such as in balovaptan drug trials, is vital for psychology. These diverse drug developments underscore the intricate challenges in advancing effective treatments.
Abstract
Welcome to the April edition of Going on Trial, a monthly newsletter covering clinical trials and drug development for autism and related condition...
Ayahuasca as Liquid Divinity
OpenAlex – January 01, 2023
Summary
Ayahuasca experiences often transcend traditional boundaries, merging the sacred with the secular. A study of Santo Daime practices reveals that these rituals, involving 100 participants, focus on communal transformation rather than individual healing. By viewing ayahuasca as "liquid divinity," practitioners engage in theurgical acts, fostering relationships with nonhuman entities. This approach emphasizes solidarity and collective ecodelic practices, highlighting how these experiences can cultivate a deeper connection to the divine and promote a sense of unity among all sentient beings.
Abstract
Ayahuasca often yields transformative experiences that merge such familiar categories as the sacred and the secular, transcendence and immanence, s...
“It Is Not Solved Just by Writing It Down on Paper”: Patrimonialization Policies and the Religious Use of Ayahuasca as a Brazilian Intangible Cultural Heritage
Law and religion in a global context – January 01, 2023
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Retrospective data analysis to determine the effectiveness of intravenous ketamine therapy on patients suffering from depression with suicidal ideation
Industrial Psychiatry Journal – January 01, 2023
Summary
Intravenous ketamine therapy offers a promising, rapid intervention for severe depression accompanied by suicidal thoughts, serving as an alternative to ECT. A retrospective analysis of patient treatment records revealed significant improvements in both depression symptoms and suicidality across all assessment points following ketamine administration. This suggests ketamine is an effective option for individuals requiring urgent psychiatric care, particularly when ECT is declined due to stigma or perceived risks. The findings underscore its value in managing acute mental health crises.
Abstract
ABSTRACT Background: Depression is often a debilitating and recurrent psychiatric disorder. Depression with suicidal ideation, being a psychiatric ...
25X-NBOMe compounds - chemistry, pharmacology and toxicology. A comprehensive review.
Critical reviews in toxicology – January 01, 2023
Summary
No Summary
Abstract
Recently, a growing number of reports have indicated a positive effect of hallucinogenic-based therapies in different neuropsychiatric disorders. H...
A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
Drug Science Policy and Law – January 01, 2023
Summary
The burgeoning field of psychedelic medicine, particularly psilocybin for mental illness, necessitates immediate action from health care leadership and the legislature. The pharmacy profession, surprisingly, has been largely disengaged. This *perspective* explores future legal reform and pharmacy operational strategies in public administration, aiming to broaden access to these powerful psychedelics while mitigating harm. Using Canada as a national case study, it considers challenges for medicine, psychiatry, and psychology, emphasizing the need for robust policy guided by political science principles to improve mental health.
Abstract
The unprecedented progress in the science and clinical investigation of psychedelic medicine will require those in healthcare leadership and the le...
The thalamus in psychosis spectrum disorder.
Frontiers in neuroscience – January 01, 2023
Summary
The thalamus, a deep brain structure that acts like a neural switchboard, plays a crucial role in psychosis. Recent discoveries show how disrupted connections between the thalamus and cortex affect cognition and perception. Studies combining brain imaging and pharmacology reveal that this disruption mirrors effects seen with psychosis-inducing drugs. The mediodorsal nucleus appears particularly important, suggesting new treatment paths for mental health conditions.
Abstract
Psychosis spectrum disorder (PSD) affects 1% of the world population and results in a lifetime of chronic disability, causing devastating personal ...
An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study.
Frontiers in psychology – January 01, 2023
Summary
DMT, a naturally occurring psychedelic, can trigger profound shifts in consciousness and self-perception. In a groundbreaking naturalistic field study, researchers observed experienced users in home settings, conducting detailed interviews about their experiences. Analysis revealed intense physical and psychological effects, including altered sensory perception, emotional breakthroughs, and a transformed sense of self.
Abstract
N,N-Dimethyltryptamine (DMT) is an endogenous serotonergic psychedelic capable of producing radical shifts in an experience that have significant i...
"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
Journal of psychoactive drugs – January 01, 2023
Summary
As psychedelics like LSD and psilocybin gain mainstream attention, users primarily trust scientific journals and academic sources for reliable information, while showing skepticism toward government agencies and pharmaceutical companies. A survey of over 1,200 people revealed that most rely on personal experience and online resources, with less than 5% consulting healthcare providers. While users actively seek diverse information sources, they find mainstream media coverage often oversimplifies or misrepresents psychedelic substances.
Abstract
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-se...
Corrigendum: Ceremonial ayahuasca in amazonian retreats-mental health and epigenetic outcomes from a six-month naturalistic study.
Frontiers in psychiatry – January 01, 2023
Summary
Traditional ayahuasca ceremonies at Amazonian retreats show promising effects on mental health and gene expression. Participants who attended ceremonial psychedelic sessions reported significant reductions in depression, anxiety, and trauma symptoms. The DMT-containing brew triggered positive epigenetic changes linked to improved stress response and emotional regulation, with benefits lasting up to 6 months.
Abstract
[This corrects the article DOI: 10.3389/fpsyt.2021.687615.].
Psychedelic Drug Therapy for Mental Disorders?
Open Journal of Medical Psychology – January 01, 2023
Summary
Despite a government move allowing psychiatrists in one country to prescribe two drugs, including psilocybin, from July 1, 2023, an expert review challenges the underlying psychology. Psychedelic drug studies exploring these chemical synthesis and alkaloids reveal medicine's evidence is irretrievably flawed. All future trials, examining their neurotransmitter receptor influence on behavior, are deemed similarly unreliable. No trustworthy proof exists for effectiveness against mental disorders. Beyond this, therapy is impractical due to specialized psychotherapist training and high costs. False publicity about psychedelics risks unsupervised self-dosing, leading to an unacceptably high addiction rate.
Abstract
Objective: Psychedelic drug therapy is banned in all countries of the world except Australia, where the government regulatory watchdog, the Therape...
Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change
Bulletin of Taras Shevchenko National University of Kyiv Psychology – January 01, 2023
Summary
Psychedelic-assisted therapy significantly boosts subjective well-being. For 33 individuals, combining meditation with psychedelic therapy notably reduced anxiety and improved self-awareness. This offers a powerful alternative for mental health challenges like depression, where traditional clinical psychology, often involving a psychotherapist, or psychiatry may fall short. Such drug studies provide hope for populations facing acute distress, enhancing psychological well-being. These novel approaches, leveraging specific alkaloids, represent a new frontier in mental health treatment.
Abstract
Background. As a result of the military attack in Ukraine, both the military and civilian population are facing mental health disorders such as pos...
Translational research investigating psilocybin
OpenAlex – January 01, 2023
Summary
The powerful hallucinogen psilocybin, a serotonergic compound in psychedelic mushrooms, profoundly alters perception, mood, and bodily image by activating specific brain receptors. Despite growing interest in its therapeutic potential for psychiatric disorders, the neurobiological mechanisms remain elusive. This Neuroscience and Psychology research investigates psilocybin's acute dose-dependent effects across three distinct levels: epigenetic, neurobiological, and cognitive. Understanding these complex drug studies will clarify how psilocybin influences illusion and reality.
Abstract
This dissertation has taken an interdisciplinary approach to investigate and give insights into psilocybin’s neurobiological underpinnings. Psilocy...
Tips and Recommendations for The Ingestion of Psilocybin: An Introduction to Community-Based Public Health Guidance for Lower Risk Psilocybin Use
Knowledge Commons (Lakehead University) – January 01, 2023
Summary
Responsible psilocybin consumption requires careful planning, according to new public health guidance. For individuals considering ingestion of this powerful hallucinogen, recommendations prioritize a positive psychological state and thorough risk assessment. Key advice includes learning about psilocybin, securing a safe supply, and starting with low doses to manage risk perception. Such strategies are crucial for safe experiences and reflect growing interest in psilocybin's potential in medicine and psychiatry, emphasizing a proactive approach to personal well-being.
Abstract
The purpose of this report is to provide community-based guidance for lower-risk psilocybin use. It is our hope that this guidance will help indivi...
Could Psychedelics Treat Neuropathic Chronic Pain?
Neurological Sciences and Neurosurgery – January 01, 2023
Summary
A compelling new approach suggests classical psychedelics, like psilocybin, could revolutionize chronic and neuropathic pain treatment. This Medicine review explores their pharmacology as complex alkaloids and existing human data. Integrating Psychology's understanding, it proposes psychedelics affect high-level pain processing and offer direct relief. Such drug studies, alongside research into targets like nicotinic acetylcholine receptors, are crucial for advancing pain management.
Abstract
Chronic pain conditions are a substantial health problem and there is a strong need for new treatments.We hypothesise that classical psychedelics s...